INB03 for the Treatment of Pulmonary Complications From COVID-19
Trial details
- Registry ID
- NCT04370236
- Drugs studied
- INB03
TrialRedline tracks 3 clinical trials sponsored by Inmune Bio, Inc.: 1 Phase 2 / 3, 2 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| INB03 for the Treatment of Pulmonary Complications From COVID-19NCT04370236 | INB03 | Terminated | 2021-10-13Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of InflammationNCT05318976 | XPro1595 | Completed | 2025-05-12Actual |
| An Open-Label Extension of XPro1595 in Patients With Alzheimer's DiseaseNCT05522387 | XPro1595 | Terminated | 2024-06-05Actual |
Names as written in the registry records.
NCT05318976 · Inmune Bio, Inc.
Before: 208 participants (actual). After: 207 participants (actual).
NCT05522387 · Inmune Bio, Inc.
Before: Active not recruiting. After: Terminated.
NCT04370236 · Inmune Bio, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Proportion of Participants With Disease Progression From Randomization to 28 Days Post-randomization. After: Measure: Cochran-Mantel-Haenszel Analysis of Proportion of Patients With Disease Progression.